Trial Profile

Phase I and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2'-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Gastrointestinal Cancers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ropidoxuridine (Primary)
Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Oesophageal cancer; Pancreatic cancer; Squamous cell cancer
Focus Adverse reactions; First in man

Most Recent Events

18 Mar 2025 Planned End Date changed from 5 Mar 2025 to 14 Mar 2026.
30 Nov 2022 Status changed from active, no longer recruiting to completed, according to a Shuttle Pharmaceuticals media release.
15 Nov 2022 Status changed from active, no longer recruiting to completed, according to a Shuttle Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com